Literature DB >> 7932192

Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor.

K Raynor1, H Kong, J Hines, G Kong, J Benovic, K Yasuda, G I Bell, T Reisine.   

Abstract

Prolonged exposure of opioid receptors to agonists can cause desensitization, a cellular event linked to tolerance. Although evidence exists for mu and delta opioid receptor desensitization, much less information is available concerning the in vitro regulation of kappa opioid receptors because no cell lines exist that specifically express this class of opioid receptor. Recently we have cloned the mouse kappa opioid receptor. After expression in COS-7 cells, this protein exhibits the pharmacological specificity of a kappa 1 receptor and mediates agonist inhibition of cAMP formation. Continuous exposure of COS-7 cells expressing the kappa receptor to the agonist trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]- benzeneacetamide methanesulfonate salt (U50,488) reduces the specific binding of the kappa-selective agonist [3H]U69,593. Furthermore, the potency of U50,488 to inhibit the binding of the opiate antagonist [3H]naloxone to the kappa receptor is reduced. However, total specific binding of [3H]naloxone is not altered, indicating that short-term (2-4 hr) agonist treatment of the kappa receptor reduces the affinity of the receptor for agonists but does not reduce the density of kappa receptors. The reduction in affinity of the kappa receptor for agonists is dependent on the time of agonist exposure and is reversible. The reduced affinity of the receptor for agonists is associated with kappa receptor desensitization, because kappa receptor-mediated inhibition of cAMP formation is lost in cells pretreated with U50,488. The desensitization of the kappa receptor is dependent on the time and concentration of agonist treatment, is blocked by the kappa-selective antagonist nor-binaltorphimine and is reversible.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932192

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Authors:  Andrew C Eschenroeder; Allison A Vestal-Laborde; Emilse S Sanchez; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2011-10-14       Impact factor: 7.452

Review 2.  Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides.

Authors:  B L Kieffer
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 3.  Regulatory mechanisms that modulate signalling by G-protein-coupled receptors.

Authors:  S K Böhm; E F Grady; N W Bunnett
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

4.  Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization.

Authors:  W Jin; S Brown; J P Roche; C Hsieh; J P Celver; A Kovoor; C Chavkin; K Mackie
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

Review 5.  Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Authors:  Michael R Bruchas; Charles Chavkin
Journal:  Psychopharmacology (Berl)       Date:  2010-04-17       Impact factor: 4.530

Review 6.  The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications.

Authors:  Miao-Jin Ji; Jiao Yang; Zhi-Qiang Gao; Liang Zhang; Chao Liu
Journal:  Front Neurosci       Date:  2021-02-24       Impact factor: 4.677

7.  Cellular and molecular mechanisms of drug dependence: An overview and update.

Authors:  Swapnil Gupta; Parmananda Kulhara
Journal:  Indian J Psychiatry       Date:  2007-04       Impact factor: 1.759

8.  Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.

Authors:  Jacobi I Cunningham; David J Eyerman; Mark S Todtenkopf; Reginald L Dean; Daniel R Deaver; Connie Sanchez; Mark Namchuk
Journal:  J Psychopharmacol       Date:  2019-07-11       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.